Equity Profile

INCY

Incyte Corporation

Health CareBiotechnology$21.1B

Apr28Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Incyte Corporation Beats on EPS, Stock Up 1.13%

Metric	Actual	Expected	Surprise
EPS	$1.81	$1.37	+58.77%
Revenue	N/A	$1.2B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Incyte Corporation Beats on EPS, Stock Up 1.13%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.81	$1.37	+58.77%
Revenue	N/A	$1.2B	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance while acknowledging the lack of revenue guidance.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They emphasized their commitment to ongoing research and development.

What It Means

Incyte's strong EPS performance exceeded analysts' expectations, contributing to a 1.13% increase in stock price. The company did not disclose revenue figures, which leaves some uncertainty for investors. Management's positive tone suggests confidence in future performance, but the lack of guidance may lead to cautious sentiment among investors.

Company Snapshot

Incyte Corporation is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Operating in the Health Care sector, Incyte's work is crucial as it addresses unmet medical needs and aims to improve patient outcomes through its drug development efforts.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

$1.37

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

In the last quarter, Incyte reported an EPS of $1.80, exceeding expectations by nearly 10%. However, the stock price fell by over 8% the following day, indicating market concerns despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Incyte's upcoming earnings, expecting a solid EPS of $1.37 and revenue of $1.2 billion. The market is closely watching for any signs of growth or challenges in their product pipeline.

Bull Case

If Incyte can beat EPS estimates and show strong revenue growth, it could signal robust demand for its therapies, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its future growth prospects, leading to a decline in stock price.

Key Metrics to Watch

EPS

$1.37

Earnings per share is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Revenue

$1.2B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Incyte's EPS exceed the consensus estimate of $1.37?

A beat on EPS could indicate strong operational performance and boost investor confidence in the company's growth trajectory.

What guidance will management provide regarding future revenue growth?

Guidance on revenue growth is crucial for understanding the company's outlook and could significantly impact market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Incyte's ability to leverage its recent product developments, which could drive stronger than expected revenue growth.

Supporting Evidence

Incyte has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.

The options market is pricing a larger move than the historical average, suggesting that traders expect significant news.

Insider selling may indicate a strategic shift rather than a lack of confidence in the company's future.

Key Risk

If Incyte's revenue growth exceeds $1.3 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Incyte can maintain its growth momentum amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case, indicating strong financial health.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.36%

Historical Avg

±5.6%

Pricing cheap

The options market is pricing in a significant move of over 7% in either direction, indicating uncertainty about the earnings report.

Options are pricing ±2.8% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

24.9%

Calls (140K)P/C Ratio: 0.33Puts (46K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 20 (35%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.8M

18,667 sh

1 insider

Net

$1.8M

Net selling

Most Active Insiders· 1 open-market trade

President, Global Head of R&DCAGNONI PABLO J
$1.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests the stock could rise by around 0.94% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management's commentary.

Miss

A miss on earnings could lead to a decline of about 0.20%, reflecting disappointment and concerns over future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Management's commentary on competitive pressures in the biotechnology space.
3Insights into sales performance for key products.
4Future guidance on revenue growth and market expansion plans.
5Details on cost management strategies and their impact on profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

$1.37

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Incyte can beat EPS estimates and show strong revenue growth, it could signal robust demand for its therapies, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its future growth prospects, leading to a decline in stock price.

Key Metrics to Watch

EPS

$1.37

Earnings per share is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.

Revenue

$1.2B

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Incyte's EPS exceed the consensus estimate of $1.37?

A beat on EPS could indicate strong operational performance and boost investor confidence in the company's growth trajectory.

What guidance will management provide regarding future revenue growth?

Guidance on revenue growth is crucial for understanding the company's outlook and could significantly impact market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Incyte's ability to leverage its recent product developments, which could drive stronger than expected revenue growth.

Supporting Evidence

Incyte has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.

The options market is pricing a larger move than the historical average, suggesting that traders expect significant news.

Insider selling may indicate a strategic shift rather than a lack of confidence in the company's future.

Key Risk

If Incyte's revenue growth exceeds $1.3 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Incyte can maintain its growth momentum amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $1.50 or higher would confirm the bull case, indicating strong financial health.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.36%

Historical Avg

±5.6%

Pricing cheap

The options market is pricing in a significant move of over 7% in either direction, indicating uncertainty about the earnings report.

Options are pricing ±2.8% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

24.9%

Calls (140K)P/C Ratio: 0.33Puts (46K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 20 (35%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.8M

18,667 sh

1 insider

Net

$1.8M

Net selling

Most Active Insiders· 1 open-market trade

President, Global Head of R&DCAGNONI PABLO J
$1.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests the stock could rise by around 0.94% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management's commentary.

Miss

A miss on earnings could lead to a decline of about 0.20%, reflecting disappointment and concerns over future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or clinical trial results.
2Management's commentary on competitive pressures in the biotechnology space.
3Insights into sales performance for key products.
4Future guidance on revenue growth and market expansion plans.
5Details on cost management strategies and their impact on profitability.